Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 8
Semaglutide Missed-Dose Evidence Gap
Two 2026 letters discuss missed oral semaglutide doses, but inaccessible text limits what can be verified beyond the current product label.
Semaglutide and Gallbladder Events
A pooled STEP analysis found more gallbladder events with semaglutide 2.4 mg than placebo, but the absolute event rate remained low.
Semaglutide and Wernicke Encephalopathy
A 2026 review found six published cases of Wernicke encephalopathy after semaglutide use for obesity, but it cannot estimate incidence or prove causation.
Sequential GLP-1/GIP Mouse Study
An engineered GLP-1/GIP molecule led its mouse-study comparisons, but the preclinical result cannot predict human weight loss or safety.
SURPASS-EARLY Tirzepatide Results
SURPASS-EARLY found larger two-year HbA1c and weight reductions with tirzepatide than flexible conventional care in early type 2 diabetes.
Tirzepatide Weight Regain at 3 Years
A post hoc SURMOUNT-1 analysis found limited regain was common during continued tirzepatide treatment, but selection limits matter.
GLP-1 Drugs in ADPKD: Evidence Review
A 2026 review proposes phenotype-enriched testing of GLP-1 drugs in ADPKD, but direct semaglutide evidence remains preclinical.
GLP-1 Drugs and AF Risk in CKD
A matched CKD cohort linked GLP-1 receptor agonist use with less atrial fibrillation, but the retrospective design cannot prove prevention.
GLP-1 Drugs Around Hand Surgery
A 2026 review finds limited, mostly retrospective evidence on GLP-1 drugs around hand surgery. Results do not settle aspiration risk or medication timing.
GLP-1 Drugs and Sexual Function Evidence
A 2026 dermatology letter flags sexual function as a missing GLP-1 safety outcome. With no abstract, related studies provide context rather than its findings.
Peptide Reaction When to Seek Care
Severe or persistent symptoms after a peptide injection need clinical assessment, not a crowd diagnosis or a guessed cause.
Retatrutide Trial Results Explained
A Phase 2 retatrutide trial reported large average weight reductions. Here is what that result can and cannot tell an individual reader.